Interventional Cardiology Resource Center Editorial Programs

 
 
  • Life and Times of Leading Cardiologists: Gilles Montalescot   Magnus Ohman speaks with Gilles Montalescot, whose illustrious career in cardiology and research in thrombosis led him from Paris to Beacon Hill and back.
  • How Did We End Up With so Many Medical Journals?   Dr DeMaria discusses his tenure at JACC, the proliferation of cardiology journals, and his current projects.
  • In Defense of Less-Is-More Cardiologist and New England Journal of Medicine correspondent, Lisa Rosenbaum, MD recently critiqued the less-is-more in medicine crusaders. One such crusader, Dr Mandrola, respectfully disagrees.
  • What COMPASS and RE-DUAL Mean for Aspirin and Triple Therapy   Drs Cohen and O'Donoghue review new data from the COMPASS and RE-DUAL PCI trials and potential strategies for patients who need anticoagulation and antiplatelet therapy.
  • The Top Cardiology Trials of 2017 in Review   In this annual tradition, Drs Harrington and Gibson discuss their picks for the top cardiology trials of the year, covering PCSK9 inhibitors, anti-inflammatory and anthithrombotic drugs, and PCI.
  • Mandrola's Top 10 Cardiology Stories of 2017 Controversy surrounding saturated fat and sham PCI make this year's list as well as a few medical reversals and the continuing opioid crisis. What topics would you add or omit?
  • ORBITA: Sham PCI Trial Sends Stents and CardioTwitter Reeling What are the biggest misperceptions about the trial that inspired 1700+ tweets in 9 days? And why did it send US interventional cardiologists into a tizzy while their UK counterparts remained calm?
  • DAPT Dilemmas Endure While BMS Should Fade Away   Dual antiplatelet therapy duration after coronary stenting remains debatable. Drs Harrington, Batchelor, and O'Donoghue discuss some of the data from TCT and predict the demise of bare metal stents.
  • When to Stent in Stable CAD? That Is (Still) the Question   Drs Harrington, Maron, and Patel discuss the ORBITA trial, which compared coronary stenting with sham percutaneous coronary intervention for angina relief. Why did ORBITA cause so much buzz?
  • AHA HOPE-Duchenne and Help at Last The final day of AHA 2017 brought Dr Walton Shirley to tears with studies offering hope to ease the suffering she has witnessed firsthand.
  • AHA Trials We Did, Trials We Should Do Dr Walton-Shirley reflects on some major studies presented at AHA 2017 and offers a further way to approach each one.
  • Revascularization in CS: Keep It Simple and Get Out of Dodge   Drs Harrington, Batchelor, and O'Donoghue discuss the implications of the TCT late-breaking CULPRIT SHOCK trial testing culprit-only vs multivessel revascularization in unstable patients in cardiogenic shock.
  • TCT Seven Reasons New Data on Watchman Are Not Persuasive PREVAIL 5-year data and a patient-level meta-analysis nudge the Watchman left atrial appendage device to meeting noninferiority, but the devil is in the details, notes Dr Mandrola.
  • AHA Mandrola Previews AHA 2017 The American Heart Association Scientific Sessions begin in Anaheim November 11. Learn which updates Dr Mandrola is most looking forward to.
  • Celebrities at Conferences: A Welcome Distraction? Medical meetings often host famous speakers, but Tom Hanks's appearance at a recent cardiology conference was for entertainment purposes only.
  • Coronary Stents Humbled Yet Again in Stable CAD ORBITA, a sham-control PCI trial, found no angina benefit for stents in patients with stable CAD. Ten years after COURAGE, it's high time cardiologists treat patients, not lesions, pleads Dr Mandrola.
  • TCT Will I Feel Better? QoL Outcomes Make the Big Stage at TCT A quality-of-life substudy of a trial comparing coronary stenting and bypass surgery could herald a new era of truly patient-centered decision-making, hopes Dr Mandrola.
  • The High Cost of Public Reporting A high-risk patient needed surgery, but Dr Koka couldn't find a surgeon willing to operate on him, for fear of looking bad on publically reported outcomes data.
  • Positive Results for PFO Closure Come With Caveats Three studies give PFO closure in cryptogenic stroke a boost, but patient selection is critical, and let's not forget about direct oral anticoagulants, cautions Dr Mandrola.
  • ESC 2017: Updates in Antithrombotic Strategies   Drs Jolly and Granger discuss three trials presented at ESC 2017 that are making waves in thrombocardiology.